Testing the Effectiveness of a Safety-promoting Intervention in Antenatal Care
Launched by NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY · Jan 19, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding how a special video intervention can help pregnant women who are experiencing domestic violence. The researchers have created a tool to identify women who may be facing violence during their pregnancy and will use this information to support them. Participants will be divided into two groups: one group will watch a video that encourages them to take steps to ensure their safety and seek help, while the other group will watch a video about having a healthy pregnancy. The goal is to see if the intervention video is more effective in promoting safety actions among women than the control video.
To be eligible for this trial, women need to be between 12 to 20 weeks pregnant and must be able to participate mentally. Unfortunately, women who are either less than 12 weeks or more than 20 weeks pregnant cannot join. If you or someone you know meets these criteria, participating in this study could provide valuable support and resources for dealing with domestic violence during pregnancy. The trial is currently recruiting participants, and it's an important step toward improving care for women in these situations.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • between 12 to 20 weeks gestational age of pregnancy
- Exclusion Criteria:
- • prior 12 weeks gestation
- • after 20 weeks of pregnancy
- • mentally unable to participate
About Norwegian University Of Science And Technology
The Norwegian University of Science and Technology (NTNU) is a leading research institution dedicated to advancing knowledge and innovation in various scientific fields. Renowned for its commitment to interdisciplinary collaboration, NTNU plays a pivotal role in addressing global health challenges through rigorous clinical trials and research initiatives. The university's emphasis on cutting-edge technology and its strong partnerships with healthcare sectors position it as a key player in translational research, ensuring that findings contribute effectively to improving public health and patient care. With a focus on ethical standards and scientific integrity, NTNU is dedicated to fostering advancements that enhance the quality of life and health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kathmandu, , Nepal
Dhulikhel, , Nepal
Patients applied
Trial Officials
Schei Berit, PhD
Principal Investigator
Norwegian University of Science and Technology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials